Stephen Majors, Director of Healthcare Practice for FrontierView, was quoted in Morning Consult‘s article, “In Oklahoma, A Warning for Proponents of Value-Based Pharma Payment.”

As pressure on Congress to address rising costs of prescription drugs mounts, lawmakers on the powerful Senate Finance Committee and pharmaceutical companies have coalesced around value-based payment, or setting drug prices based on efficacy, as a method to reduce drug costs.

Stephen Majors, director of health care practice at FrontierView, explained that value-based pricing involves setting initial prices based on the magnitude of the benefits, taking a more holistic approach to assessing impact on the health care system by considering the cost of care for a patient in the absence of a treatment. Outcomes-based contracts focus on narrower goals based on the achievement of milestones, such as whether a patient is cured, and offer refunds or rebates from manufacturers if certain outcomes are unmet — as in Oklahoma.

To read the full article, click here.

FrontierView has all the information you need about your market, industry, and company in real-time to power your business decisions. We offer a solution that puts the right information at the right time, at your fingertips. If you would like more insights into your specific markets, click the “Start Free Trial” button on your screen to speak with a dedicated Client Services Manager and receive complimentary access to our offering.

Categories: